Last reviewed · How we verify
ICLAPRIM
ICLAPRIM works by inhibiting the enzyme dihydrofolate reductase, which is essential for bacterial DNA synthesis.
ICLAPRIM is a small molecule drug that targets dihydrofolate reductase, an enzyme involved in DNA synthesis. It is classified as an iclaprim and has been developed to treat bacterial infections. However, its commercial status and approved indications are unknown. As a result, its half-life, bioavailability, and generic manufacturers are also not available. Further research is needed to determine its current status and potential applications.
At a glance
| Generic name | ICLAPRIM |
|---|---|
| Drug class | iclaprim |
| Target | Dihydrofolate reductase, Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Mechanism of action
Think of it like a roadblock for bacteria. ICLAPRIM blocks the enzyme that helps bacteria make new DNA, which is necessary for them to grow and multiply. This makes it harder for the bacteria to cause infections.
Approved indications
Common side effects
Key clinical trials
- Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer (PHASE1,PHASE2)
- Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2 (PHASE3)
- Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1 (PHASE3)
- Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia (PHASE2)
- Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1) (PHASE3)
- Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICLAPRIM CI brief — competitive landscape report
- ICLAPRIM updates RSS · CI watch RSS